Contents lists available at ScienceDirect

Cell Calcium

Selective inhibition of histamine-evoked Ca^{2+} signals by compartmentalized cAMP in human bronchial airway smooth muscle cells

Philippa Dale[a], Victoria Head[b], Mark R. Dowling[c], Colin W. Taylor[a],*

[a] Department of Pharmacology,Tennis Court Road, Cambridge, CB2 1PD, UK
[b] Novartis Institutes for BioMedical Research, Fabrikstrasse, CH-4056, Basel, Switzerland
[c] Novartis Institutes for BioMedical Research Inc., 250 Massachusetts Avenue, Cambridge, MA, 02139, USA

ARTICLE INFO

ABSTRACT

Intracellular Ca^{2+} and cAMP typically cause opposing effects on airway smooth muscle contraction. Receptors that stimulate these pathways are therapeutic targets in asthma and chronic obstructive pulmonary disease. However, the interactions between different G protein-coupled receptors (GPCRs) that evoke cAMP and Ca^{2+} signals in human bronchial airway smooth muscle cells (hBASMCs) are poorly understood. We measured Ca^{2+} signals in cultures of fluo-4-loaded hBASMCs alongside measurements of intracellular cAMP using mass spectrometry or [^{3}H]-adenine labeling. Interactions between the signaling pathways were examined using selective ligands of GPCRs, and inhibitors of Ca^{2+} and cAMP signaling pathways. Histamine stimulated Ca^{2+} release through inositol 1,4,5-trisphosphate (IP$_3$) receptors in hBASMCs. β$_2$-adrenoceptors, through cAMP and protein kinase A (PKA), substantially inhibited histamine-evoked Ca^{2+} signals. Responses to other Ca^{2+}-mobilizing stimuli were unaffected by cAMP (carbachol and bradykinin) or minimally affected (lysophosphatidic acid). Prostaglandin E$_2$ (PGE$_2$), through EP$_2$ and EP$_4$ receptors, stimulated formation of cAMP and inhibited histamine-evoked Ca^{2+} signals. There was no consistent relationship between the inhibition of Ca^{2+} signals and the amounts of intracellular cAMP produced by different timuli. We conclude that β-adrenoceptors, EP$_2$ and EP$_4$ receptors, through cAMP and PKA, selectively inhibit Ca^{2+} signals evoked by histamine in hBASMCs, suggesting that PKA inhibits an early step in H$_1$ receptor signaling. Local delivery of cAMP within hyperactive signaling junctions mediates the inhibition.

1. Introduction

Bronchial asthma and chronic obstructive pulmonary disease (COPD) are associated with inflammation, hyper-responsiveness and airway obstruction leading to restricted airflow. Although the nature of the inflammation and disease progression [1–3] differ for asthma and COPD, a major therapeutic target for both diseases is airway smooth muscle (ASM). Enhanced contractile activity and/or proliferation of ASM provoked by increased levels of acetylcholine, histamine, bradykinin or cytokines; by increased responsiveness to acetylcholine; or, after prolonged treatment with β-agonists, by attenuated activity of β$_2$-adrenoceptors can all contribute to airway obstruction in asthma and COPD [[1–3],[1–3]]. Alongside anti-inflammatory therapies (e.g. inhaled glucocorticosteroids for asthma), management of both diseases

relies heavily on inhaled drugs that induce relaxation of ASM via stimulation of β$_2$-adrenoceptors (e.g. salbutamol or indacaterol) or antagonists of M$_3$ muscarinic receptors (e.g. glycopyrronium bromide) to block contraction evoked by endogenous acetylcholine [[1–3],4]. Current therapies can provide some symptomatic relief for COPD, but they fail to prevent disease progression, and there are concerns about long-term use of β-agonists in asthmatic patients [5].

An increase in intracellular free Ca^{2+} concentration ([Ca^{2+}]$_i$) stimulates contraction of ASM, but additional mechanisms regulate the Ca^{2+}-sensitivity of the contractile machinery, notably through RhoA and inhibition of myosin light chain (MLC) phosphatase [6]. Defects in Ca^{2+} signaling and the sensitization pathways are proposed to contribute to airway hyper-responsiveness [7–10]. Ca^{2+} signals are usually initiated by receptors that stimulate phospholipase Cβ (PLCβ) and

thereby formation of inositol 1,4,5-trisphosphate (IP_3), which evokes Ca^{2+} release from the sarcoplasmic reticulum through IP_3 receptors (IP_3R). In human ASM, the major physiological contractile stimulus is acetylcholine released from parasympathetic terminals, which then stimulates $PLC\beta$ through M_3 receptors and $G_{q/11}$ [11], and possibly also through M_2 receptors and G_i [12]. In diseased airways, contraction may be evoked by additional stimuli because the stimuli accumulate within the airways (e.g. bradykinin and histamine) [1] and/or their receptors are up-regulated (e.g. B_2 bradykinin receptors) [13].

In ASM from various mammals, β-agonists cause relaxation and attenuate the increase in $[Ca^{2+}]_i$ evoked by receptors that stimulate PLC [5]. The mechanisms are not resolved, but there is evidence for reduced accumulation of IP_3 [14], increased activity of the SR/ER Ca^{2+}-ATPase (SERCA) [15], and inhibition of IP_3Rs [16]. It has been widely supposed that cAMP and cAMP-dependent protein kinase (PKA) mediate these effects of β-agonists, but the evidence has been inconclusive [see discussion in 5] and there are suggestions that exchange proteins activated by cAMP (Epacs) may be more important than PKA [17,18]. Because ASM from different species respond to different stimuli [19] it is important to examine human cells, but there have been relatively few analyses of Ca^{2+} signaling in human ASM. The most informative studies have used either precision-cut lung slices, where the complex relationships between ASM and associated cells are maintained [19]; or cultured ASM, which bring the benefits of simplicity and availability, but with a risk that phenotypes may change in culture [20]. Hitherto, a major limitation of cultured human ASM has been loss of the muscarinic receptors [20,21] that both contribute to the contractile responses in COPD and asthma, and provide important targets for therapy.

Concern about long-term use of long-acting β-agonists has prompted interest in alternative therapies for asthma and COPD. These include prostaglandin E_2 (PGE_2), which can also stimulate adenylyl cyclase (AC), primarily through EP_2 and EP_4 receptors [22]. High concentrations of PGE_2 are found in human lower respiratory tract [23] and they are increased further in eosinophilic bronchitis [24]. PGE_2 relaxes human airways [22]; EP_2 and EP_3 receptors are upregulated in ASM from asthmatic patients [25]; and inhaled PGE_2 may benefit patients with asthma or chronic bronchitis [22]. However, species differ in the responses of their ASM to PGE_2 and in the EP receptors they express [22,26]. Even within human airways, there is conflicting evidence for the relative contributions of EP_2 [27] and EP_4 [22] receptors to relaxant responses. The effects of PGE_2 on the Ca^{2+} signals evoked by contractile stimuli in human ASM are unknown. There is, therefore, a need in human ASM to establish whether PGE_2 affects Ca^{2+} signals and through which receptors. Furthermore, there is evidence that β-agonists and PGE_2 stimulate different isoforms of AC, thereby producing cAMP in different intracellular locations and with different functional consequences [see references in 28]. Hence, there is a need to determine in human ASM the interplay between the different G protein-coupled receptors (GPCRs) that stimulate Ca^{2+} and cAMP signals.

2. Methods

2.1. Materials

FLIPR calcium 4 assay kit was from Molecular Devices (Wokingham, UK). Fluo-4-AM, fura-2-AM and Hank's balanced salt solution (HBSS) with Ca^{2+} and Mg^{2+} were from Life Technologies (Paisley, UK). BAPTA was from Molekula (Dorset, UK). Ultragold scintillant and $[2,8\text{-}^3H]$ adenine were from Perkin Elmer (Buckinghamshire, UK). Ionomycin was from Apollo Scientific (Stockport, UK). Smooth muscle growth medium 2 (SMGM-2) and supplement were from Promocell (Heidelberg, Germany). Pertussis toxin (PTX) was from List Biological Laboratories (Campbell, CA, USA). Histamine dihydrochloride, carbamylcholine chloride (carbachol), (−)-isoproterenol hydrochloride, PGE_2, 3-isobutyl-1-methylxanthine (IBMX), bradykinin acetate, Dowex

50WX4-400, alumina, imidazole, probenecid, anhydrous dimethyl sulfoxide (DMSO), pluronic F127, triton-X-100, poly-L-lysine, 8-Br-cAMP, 8-Br-cGMP, dibutyryl cAMP, KT5720 ((9R,10S,12S)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo [1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, hexyl ester), $GdCl_3$, nimodipine, 2-aminoethoxyphenylborane (2-APB), ATP and acetonitrile were from Sigma (Poole, UK). 18:1 lysophosphatidic acid (LPA) was from Avanti Polar Lipids (Alabaster, AL, USA). 8-pCPT-2′-O-Me-cAMP, ESI-05 (4-methylphenyl-2,4,6-trimethylsulphone), Rp-8-CPT-cAMPs and 6-Bnz-cAMP were from Biolog (Bremen, Germany). TCS2510 ((5R)-5-[(3S)-3-hydroxy-4-phenyl-1-buten-1-yl]-1-[6-(2H-tetrazol-5-yl)hexyl]-2-pyrrolidinone), H89 dihydrochloride (N-[2-[[3-(4-bromophenyl)-2-propenyl]amino] ethyl]-5-isoquinolinesulfonamide dihydrochloride), myristoylated protein kinase inhibitor 14–22 amide (PKI-myr), ryanodine, trans-Ned-19 and edelfosine were from Tocris/Biotechne (Minneapolis, MN, USA). Sulprostone was from Enzo Life Sciences (Exeter, UK). R-butaprost (free acid), NKH477 (N,N-dimethyl-(3R,4aR,5S,6aS,10S,10aR,10bS)-5-(acetyloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-1H-naphtho[2,1-b]pyran-6-yl ester β-alanine hydrochloride) and forskolin were from Cayman Chemicals (Ann Arbor, MI, USA). When DMSO or ethanol was used as a solvent, all related assays included solvent at the same final concentration; neither solvent, at the highest concentrations used, affected biological responses.

2.2. Culture of hBASMCs

Human bronchial ASM cells (hBASMC, passage 3) from three male donors (aged 11, 4 and 37 years, donors 1–3, respectively) were from Lonza (catalogue number CC-2576, Basel, Switzerland). The cells had been isolated from the major bronchi of undiseased tissue and shown to stain for α-smooth muscle actin, but not for von Willebrand Factor VIII. Cells were grown in SMGM-2 (Lonza) supplemented with fetal calf serum (5%, Sigma), and recombinant human forms of epidermal growth factor (0.5 ng·mL^{-1}), basic fibroblast growth factor (2 ng·mL^{-1}) and insulin (5 μg mL^{-1}) (all from Promocell, Heidelberg, Germany). Cells were grown at 37 °C in humidified air containing 5% CO_2, and passaged when they were 80–90% confluent. Cells from passages 4–10 were used for experiments. There were no obvious changes in morphology, growth rate or signaling responses within this range of passages.

2.3. Measurements of $[Ca^{2+}]_i$ in populations of hBASMCs

Two methods were used to measure $[Ca^{2+}]_i$ in populations of hBASMCs. For measurements using a FlexStation III plate-reader (Molecular Devices, Sunnyvale, CA, USA), hBASMCs were seeded into 96-well plates (10^4 cells per well). After about 4 days, when the cells were confluent, the medium was replaced with SMGM-2 without serum or growth factor supplements, and the cells were used after a further 24 h. This period in serum-free medium increased by about 2-fold the amplitude of the increases in $[Ca^{2+}]_i$ evoked by histamine (results not shown). Cells were washed with HEPES-buffered saline (HBS: 135 mM NaCl, 5.9 mM KCl, 1.2 mM $MgCl_2$, 1.5 mM $CaCl_2$, 11.6 mM HEPES, 11.5 mM D-glucose, pH 7.3), and loaded with fluo-4 by incubation with fluo-4-AM (2 μM) in HBS (100 μL per well) containing pluronic F127 (0.02%, v/v) and probenecid (2.5 mM). After 1 h at 20 °C, the medium was replaced with HBS (100 μL per well) containing probenecid (2.5 mM). After a further incubation at 20 °C for 1 h, the medium was replaced with HBS (60–80 μL per well) or nominally Ca^{2+}-free HBS, and the cells were used immediately for experiments at 20 °C. In some experiments, BAPTA (2.5 mM) was added to HBS during the recording; this reduced the free $[Ca^{2+}]$ of the HBS to ~120 nM without affecting the pH. Drug additions (20 μL at 4 or 5 times the final concentration) were added automatically. Fluorescence from fluo-4 (excitation 485 nm, emission 525 nM) was recorded at 1.44-s intervals using

Softmax Pro 5.4 (Molecular Devices). Fluorescence was calibrated to $[Ca^{2+}]_i$ from:

$$[Ca^{2+}]_i = K_D^{Ca} \times \left(\frac{F - F_{min}}{F_{max} - F} \right)$$

where, K_D^{Ca} is the equilibrium dissociation constant of fluo-4 for Ca^{2+} (345 nM) [29], F is the recorded fluorescence, and F_{min} and F_{max} are the fluorescence values recorded after addition of triton-X-100 (0.1%, v/v) with either BAPTA (10 mM, F_{min}) or $CaCl_2$ (10 mM, F_{max}). Although treatment with triton-X-100 releases fluo-4 from cells into the medium, the fluo-4 fluorescence is captured with the same efficiency whether it is trapped within cells or dispersed within the small volume of the wells (unpublished observations). F_{max} was determined for each well at the end of an experiment, and the average value was used for each column of 8 wells. F_{min} was determined from parallel wells on each plate.

For measurements of $[Ca^{2+}]_i$ using an FDSS 7000 FLIPR (Hamamatsu), hBASMCs were seeded into 384-well plates (8000 cells per well) in 20 µL of SMGM-2 containing 5% serum. After 24 h, the medium was replaced with 15 µL of serum-free SMGM-2, and after a further 6 h the cells were loaded with Ca^{2+} indicator by addition of FLIPR calcium 4 assay kit (Molecular Devices) supplemented with probenecid (2.5 mM). The exact composition of this 'no-wash' indicator kit is not disclosed by the manufacturer, but it contains fluo-4-AM and components that reduce background fluorescence. The manufacture's stock solution was diluted 10-fold into HBSS containing BSA (0.1%, w/v) and HEPES (20 mM); 5 µL of this solution was then added to each well (containing 15 µL of serum-free SMGM-2). After 2 h at 37 °C in humidified air containing 5% CO_2, the plate was used for experiments at 20 °C. Most additions (5 µL) were prepared in HBSS supplemented with HEPES (20 mM) and BSA (0.1%, w/v). For more prolonged incubations, drugs were diluted in the initial loading medium (to avoid changes in dye-loading during the 'no wash' protocol). Fluorescence signals (excitation at 480 nm, emission at 540 nm) were calibrated to $[Ca^{2+}]_i$ after measurement of F_{min} and F_{max} uniquely for each well, using a $K_D^{Ca} = 345$ nM.

All concentration-effect relationships were determined by addition of different drug concentrations to individual wells in the same multi-well plate, rather than by sequential additions to the same well.

2.4. Measurements of intracellular cAMP by [³H]-adenine labeling

hBASMCs in 24-well plates (50,000 cells per well) were grown to confluence. The medium was then replaced with serum-free SMGM-2, and after 24 h this was supplemented with [³H]-adenine (1 µCi per well, 18.4 Ci·mmol⁻¹). After 2 h at 37 °C in humidified air with 5% CO_2, the medium was removed, and the cells were washed twice with HBS. The cells were stimulated at 20 °C in HBS. Incubations were terminated by removal of the medium, addition of ice-cold trichloroacetic acid (5%, 1 mL) and rapid freezing. This protocol ensured that only intracellular [³H]-cAMP was detected. [³H]-adenine nucleotides were separated by column chromatography [30], and the activity was determined by liquid scintillation counting using Ultra-gold scintillant. Results are presented as [³H]-cAMP activity as a percentage of the sum of the activities of the fractions containing [³H]-cAMP, [³H]-ATP, [³H]-ADP and [³H]-AMP; henceforth, reported as [³H]-cAMP (%).

2.5. Measurements of intracellular cAMP by mass spectrometry

These methods were modified from [31]. Confluent cultures of hBASMCs in 48-well plates were serum-deprived (6–24 h) and the medium was then replaced with HBSS (300 µL) containing HEPES (5 mM) and BSA (0.1%, w/v). Cells were stimulated at 20 °C, and reactions were terminated by aspiration of the medium and addition of acetonitrile (170 µL) containing dibutyryl cAMP (0.5 µM, to provide an internal standard). The plates were centrifuged (1500 xg, 15 min, 4 °C),

supernatants (158 µL) were transferred to a 96-well, glass-coated plate (Thermo Scientific), and aqueous NH_4HCO_3 (pH 9.4, 93 µL) was added to each sample. After mixing and centrifugation (1500 xg, 15 min, 4 °C), samples were stored at 4 °C before analysis.

Samples were analyzed by liquid chromatography tandem mass spectrometry (LC–MS/MS) using a Waters Acquity UPLC and a Sciex 5500 mass spectrometer equipped with an electrospray ionization source. ATP, ADP, AMP and cAMP were analyzed using a ZIC-pHILIC polymeric column (5-µm particle size, 5.0 × 2.1 mm) maintained at 35 °C. Calibration standards were prepared in the lysis medium containing the internal standard, dibutyryl cAMP (0.5 µM). The injector was maintained at 4 °C and injection volumes were 5 µL. The mobile phase comprised solvents A (20% acetonitrile, 80% aqueous NH_4HCO_3, pH 9.4) and B (100% acetonitrile). The mobile phase (0.4 mL·min⁻¹) was 40% A (0.2 min), then a linear gradient from 40% to 100% A (0.8 min), followed by 100% A (1 min). The gradient was returned to the initial conditions over 0.5 min, and maintained for a further 1.5 min. Samples were detected using multiple reaction monitoring in negative ion mode using the following parent-to-daughter mass transitions: cAMP m/z 327.9 → 133.9 (DP −100 V, CE −33 eV), AMP m/z 345.9 → 134.0 (DP −100 V, CE −50 eV), ADP m/z 426.0 → 134.0 (DP −100 V, CE −30 eV), ATP m/z 505.9 → 408.0 (DP −100 V, CE −35 eV), and internal standard dibutyryl cAMP m/z 468.1 → 175.0 (DP −100 V, CE −35 eV).

2.6. Data and statistical analysis

Concentration-effect relationships were fitted to logistic equations for each experiment using GraphPad Prism (version 5, GraphPad Software, La Jolla, CA, USA), from which half-maximally effective drug concentrations (EC_{50}), maximal responses, and Hill slopes were determined. For statistical analyses, maximal responses, Hill slopes and pEC_{50} (-$logEC_{50}$) or pIC_{50} (-log of the half-maximal inhibitory concentration, IC_{50}) values determined for individual experiments were pooled for statistical analysis. Two-tailed Student's t-tests or one-way ANOVA with Bonferroni's or Dunnett's multiple comparison tests were used as appropriate. $P < 0.05$ was considered significant. Results are reported as mean ± SEM with n indicating the number of independent experiments (ie performed with different culture plates on different days, and usually with all reagents independently prepared). Most statistical analyses used GraphPad Prism (version 5).

3. Results

3.1. GPCRs evoke Ca^{2+} signals in hBASMCs through IP_3Rs

Stimuli of several GPCRs reported to be expressed in ASM evoked increases in $[Ca^{2+}]_i$ in hBASMCs (Fig. 1A). Cells from all three donors responded to histamine, LPA and bradykinin, but cells from only one donor responded robustly to ATP (donor 3) and cells from only one other donor responded robustly to carbachol (donor 2) (Fig. 1A). The response to carbachol was unexpected because although native hBASMCs express M_2 and M_3 muscarinic receptors [12], their expression is usually lost when cells are cultured (see Section 1). Our identification of functional muscarinic receptors provides the first opportunity to examine the effects of the most important physiological stimulus for contraction in cultured hBASMCs.

The peak increases in $[Ca^{2+}]_i$ evoked by histamine, bradykinin or carbachol were unaffected by removal of extracellular Ca^{2+}, confirming that the initial response was entirely mediated by release of Ca^{2+} from intracellular stores (Fig. 1B). The responses were also unaffected by block of L-type Ca^{2+} channels with nimodipine (Fig. 1C). In a parallel experiment with single fura-2-loaded hBASMCs, replacing extracellular Na^+ with K^+ (140 mM) to evoke depolarization caused a detectable increase in $[Ca^{2+}]_i$ in 29 of 44 cells (from a single experiment). This response was reversibly inhibited by nimodipine (10 µM,

Fig. 1. GPCRs stimulate increases in $[Ca^{2+}]_i$ in hBASMCs through activation of PLC and IP_3Rs. A, Populations of fluo-4-loaded hBASMCs in 384-well plates were stimulated with the indicated drug concentrations in HBSS. Peak increases in $[Ca^{2+}]_i$ are shown ($\Delta[Ca^{2+}]_i$) as means $\pm$ SEM for cells from donors 1, 2 and 3 ($n = 4$, 3 and 3, respectively). B, Effects of histamine, bradykinin and carbachol on $\Delta[Ca^{2+}]_i$ and the sensitivity to each (pEC_{50}) in either HBS or Ca^{2+}-free HBS (2.5 mM BAPTA added 37 s before the stimulus). Cells were from donor 1 for histamine and bradykinin ($n = 3$) and from donor 2 for carbachol ($n = 4$). C, D, Effects of nimodipine (10 μM, 5 min), *trans* Ned-19 (1 μM, 5 min) or ryanodine (50 μM, 5 min) on the Ca^{2+} signals evoked by the indicated stimuli in HBSS. Results (B-D) show means $\pm$ SEM, $n = 7$ (histamine, donor 1), $n = 4$ (bradykinin, donor 1) and $n = 3$ (carbachol, donor 2). *$P < 0.05$, one-way repeated ANOVA with Dunnett's test (C) or paired two-tailed Student's *t*-test (D), each relative to control. E, Effects of pre-incubation (30 min) with the indicated concentrations of edelfosine on basal $[Ca^{2+}]_i$ and the peak increases in $[Ca^{2+}]_i$ evoked by carbachol (10 μM). Results (mean $\pm$ SEM, $n = 3$) are from donor 2. F, Effects of the indicated concentrations, of 2-APB added 5 min before histamine (10 μM, $n = 7$), carbachol (10 μM, $n = 3$) or bradykinin (1 nM, $n = 4$) in HBSS, or to ionomycin (1 μM, $n = 7$) added in Ca^{2+}-free HBSS to determine the Ca^{2+} content of the intracellular stores. Results are from donors 1 and 2.

5 min): the peak increase in $[Ca^{2+}]_i$ recorded from all 44 cells was 50 $\pm$ 11 nM and 20 $\pm$ 14 nM in the absence and presence of nimodipine, respectively (mean $\pm$ SD from a single experiment, $P < 0.05$, Student's *t*-test). Neither ryanodine to inhibit ryanodine receptors (RyR) (Fig. 1D) nor *trans* Ned-19 to inhibit two-pore channels (TPC) [32,but

see reference 33] (Fig. 1C) substantially affected the Ca^{2+} signals evoked by histamine, bradykinin or carbachol, although the sensitivity to histamine was slightly reduced by both inhibitors. The concentrations of the inhibitors used were shown by others to effectively inhibit their targets [see references in 34] A lack of response to caffeine (data

not shown) and the insensitivity of most responses to ryanodine (Fig. 1D) may reflect a loss of functional RyRs during culture of hBASMCs, as noted previously for other smooth muscle cells [34]. However, even in human lung slices, which do express RyRs, histamine-evoked Ca^{2+} signals were unaffected by inhibition of RyRs [19].

Edelfosine, an inhibitor of PLC [35], caused a concentration-dependent inhibition of the responses evoked by carbachol (Fig. 1E), histamine and bradykinin. The pIC_{50} values for inhibition by edelfosine of the Ca^{2+} signals evoked by histamine (10 μM), bradykinin (1 nM) and carbachol (10 μM) were 4.64 ± 0.13, 4.47 ± 0.06 and 4.40 ± 0.04, respectively ($n = 3$). There are no selective and effective membrane-permeant inhibitors of IP_3Rs [36]. 2-APB inhibits IP_3Rs, but it also modulates store-operated Ca^{2+} entry, and it inhibits the Ca^{2+} pump that mediates Ca^{2+} uptake into the ER [37]. The results shown in Fig. 1F demonstrate that under conditions where Ca^{2+} entry does not contribute to the GPCR-evoked Ca^{2+} signals (Fig. 1B), 2-APB abolished the increases in $[Ca^{2+}]_i$ evoked by histamine, bradykinin and carbachol. 2-APB also reduced the Ca^{2+} content of the intracellular stores (assessed by addition of ionomycin in Ca^{2+}-free HBS), but this effect was less substantial and required higher concentrations of 2-APB than the inhibition of GPCR-evoked Ca^{2+} signals (Fig. 1F).

Pre-treatment of hBASMCs with pertussis toxin (PTX) had no effect on the Ca^{2+} signals evoked by histamine or bradykinin, but it significantly reduced both the maximal amplitude of the Ca^{2+} signals evoked by carbachol and LPA and their sensitivity to these stimuli (Fig. 2). The incomplete block of responses to carbachol and LPA by PTX is unlikely to result from incomplete modification of G_i proteins, because in parallel experiments the same treatment with PTX abolished the inhibition of AC activity by carbachol, probably acting via M_2 muscarinic receptors [12] (data not shown).

The results so far demonstrate that histamine, bradykinin, carbachol, ATP and LPA can evoke Ca^{2+} signals in hBASMCs. The initial responses are likely to be mediated by Ca^{2+} release through IP_3Rs after stimulation of $PLC\beta$ by $G_{q/11}$. In addition, release of $G\beta\gamma$ subunits from G_i contributes to responses evoked by carbachol, and more so to the Ca^{2+} signals evoked by LPA. The results with carbachol are consistent with evidence from human lung tissue showing that M_3 receptors mediate most carbachol-evoked contraction, with lesser [12] or undetectable [38] contributions from M_2 receptors.

3.2. Isoproterenol inhibits histamine-evoked Ca^{2+} signals through cAMP and PKA

Activation of β-adrenoceptors with isoproterenol stimulated a concentration-dependent accumulation of intracellular cAMP within hBASMCs (Fig. 3A). Isoproterenol also inhibited histamine-evoked


Fig. 2. Pertussis toxin selectivity attenuates the Ca^{2+} signals evoked by LPA and carbachol. A-D, Effects of pre-treatment with pertussis toxin (PTX, 100 ng·mL^{-1}, 24 h) on the peak increases in $[Ca^{2+}]_i$ evoked by the indicated stimuli. Results are from cells derived from donors 1 and 2 ($n = 3$ for *B* and *C*; $n = 4$ for A and D). E, F, Summary results. *$P < 0.05$, paired Student's *t*-test, relative to control.

Fig. 3. Inhibition of histamine-evoked Ca^{2+} signals by isoproterenol. A, Effects of isoproterenol (5 min) on intracellular cAMP concentrations in hBASMCs. Results are from MS analyses, $n = 3$. B, Typical traces from populations of fluo-4-loaded hBASMCs stimulated in HBS with histamine alone (10 µM, black trace) or after pre-incubation with isoproterenol (10 µM, 5 min, red trace) ($n = 6$). C, Summary results from similar experiments performed in HBSS ($n = 7$) show $\Delta[Ca^{2+}]_i$ evoked by histamine alone or after treatment with isoproterenol. D, Concentration-dependent effects of isoproterenol (added 5 min before histamine) on $\Delta[Ca^{2+}]_i$ evoked by histamine (10 µM) in HBSS. Results, are expressed as percentages of the matched control response without isoproterenol ($n = 4$). Results are from donor 1 (A, C and D) or donors 1 and 2 (B).

Ca^{2+} signals by significantly reducing both the maximal amplitude of the peak increase in $[Ca^{2+}]_i$ (from 242 ± 15 nM to 168 ± 19 nM, $n = 7$) and the sensitivity to histamine ($pEC_{50} = 5.98$ and 5.37) (Fig. 3B, C). Histamine-evoked Ca^{2+} signals were more sensitive to isoproterenol ($pIC_{50} = 8.09 ± 0.21$, $n = 4$) than was cAMP accumulation ($pEC_{50} = 6.88 ± 0.39$, $n = 3$) (Fig. 3A, D).

The inhibition of histamine-evoked Ca^{2+} signals by isoproterenol was mimicked by a membrane-permeant analogue of cAMP, 8-Br-cAMP ($pIC_{50} = 3.32 ± 0.16$, $n = 6$), but not by 8-Br-cGMP (Fig. 4A). Inhibition of cyclic nucleotide phosphodiesterases with IBMX also caused an accumulation of intracellular cAMP and an inhibition of histamine-evoked Ca^{2+} signals (Fig. 4B). Direct activation of AC by forskolin (Fig. 4C) or its more water-soluble analogue NKH477 (Fig. 4D) also mimicked the effect of isoproterenol. Neither isoproterenol nor forskolin (10 µM, 5 min) affected the Ca^{2+} content of the intracellular stores, assessed by addition of ionomycin in Ca^{2+}-free HBS (results not shown). The maximal inhibitory effects of forskolin and isoproterenol on histamine-evoked Ca^{2+} signals were similar and no larger with both stimuli together (Fig. 4C), although their combined effects on cAMP accumulation were larger than with either stimulus alone (Fig. 4C, E). These results suggest that either stimulus can evoke formation of more cAMP than needed to maximally inhibit the histamine-evoked Ca^{2+} signals, consistent with our evidence that the inhibition of Ca^{2+} signals is more sensitive than the formation of cAMP to isoproterenol (Fig. 1A and 3D). These results are consistent with cAMP preceding inhibition of Ca^{2+} signals in the signaling pathway [39], and with maximal activation by isoproterenol generating more cAMP than required to maximally inhibit the Ca^{2+} signals. Our results confirm those from human lung slices, where histamine-evoked Ca^{2+} signals and contractions were attenuated by formoterol [19], and they extend them by demonstrating that the effects of β_2-adrenoceptors are entirely mediated by cAMP.

While our work was in progress, the first direct evidence confirming a role for PKA in mediating the effects of β_2-adrenoceptors on Ca^{2+} signals and relaxation of cultured smooth muscle from human trachea and bronchi was published [5]. The authors demonstrated that stable expression of a peptide inhibitor of PKA (PKI) abolished the inhibition of histamine-evoked Ca^{2+} signals by isoproterenol, knockdown of Epacs 1 and 2 had no effect on the inhibition by isoproterenol of the histamine-stimulated phosphorylation of myosin light chain 2, and nor did an Epac-selective cAMP analogue mimic the effect of isoproterenol. Our results are consistent with their conclusion that Epacs do not contribute to the inhibition of histamine-evoked Ca^{2+} signals by isoproterenol. Pre-treatment of hBASMCs with a cAMP analogue selective for PKA, 6-Bnz-cAMP (500 µM, 20 min) [40], reduced the amplitude of the Ca^{2+} signals evoked by histamine (10 µM) to 54 ± 4% of these recorded from paired controls ($n = 5$), whereas the Epac-selective analog 8-pCPT-2′-O-Me-cAMP (300 µM) had no effect (103 ± 8%). Two of the commonly used antagonists of Epacs (ESI-09 and HJC0197) [41] have intolerable off-target effects [42,43]. However, an Epac-2 inhibitor, ESI-05 [41], had no effect on the concentration-dependent inhibition of histamine-evoked Ca^{2+} signals by isoproterenol (Figs. Fig. 4F and Fig. 5A). Our results with inhibitors of PKA, in keeping with similar published approaches [44], were inconclusive (Fig. 5A). Inhibitors expected to interact with the ATP-binding site of PKA (H89 and KT5720), its cAMP-binding site (R_P-8-CPT-cAMPS) or its peptide-binding site (PKI-myr) had no significant effect on the inhibition of histamine-evoked Ca^{2+} signals by a maximally effective concentration of isoproterenol (Fig. 5A). H89 significantly reduced the sensitivity to isoproterenol, but that may be due to it being a competitive antagonist of β-adrenoceptors [45]. R_P-8-CPT-cAMPS also caused a significant decrease in the sensitivity to isoproterenol, but the effect was small (Fig. 5A). Neither KT5720 nor PKI-myr significantly affected the sensitivity to isoproterenol. Both we and others have failed to achieve effective inhibition of PKA in intact smooth muscle cells with these inhibitors [[5],43,44]. However, in light of the recently published work

Fig. 4. Isoproterenol inhibits histamine-evoked Ca^{2+} signals through cAMP. A, Peak increases in $[Ca^{2+}]_i$ evoked by histamine (10 μM) after pre-treatment with the indicated concentrations of 8-Br-cAMP or 8-Br-cGMP (20 min) ($n = 4$). B, Effects of the indicated concentrations of IBMX (20 min) on the intracellular concentration of cAMP (measured by MS) and the peak increase in $[Ca^{2+}]_i$ evoked by histamine (10 μM). Results are expressed as percentages of the $\Delta[Ca^{2+}]_i$ evoked by histamine alone ($n = 6$, donor 1) or as percentages of the cAMP concentration determined with the maximal concentration of IBMX (1 mM) ($n = 5$, donor 1). C, Effects of pre-incubation (30 min) with isoproterenol (10 μM), forskolin (10 μM) or both on the peak increase in $[Ca^{2+}]_i$ evoked by histamine in HBSS, and their sensitivity to histamine (pEC_{50}) (donor 1, $n = 4$). Parallel experiments show effects of the same treatments on intracellular cAMP accumulation determined after ^{3}H-adenine-labeling of cells in HBS (donor 1, $n = 3$). $^*P < 0.05$, one-way repeated measures ANOVA with Dunnett's test, relative to response evoked in the presence of isoproterenol. D, Peak increases in $[Ca^{2+}]_i$ evoked by the indicated concentrations of histamine in HBS after pre-treatment (5 min) with solvents (DMSO or EtOH), isoproterenol (10 μM), NKH477 (10 μM), TCS 2510 (1 μM) or butaprost (10 μM) ($n = 4$). E, Intracellular cAMP accumulation in hBASMCs stimulated for 5 min in HBS with NKH477 (10 μM), forskolin (10 μM), isoproterenol (10 μM), PGE_2 (10 μM), TCS 2510 (1 μM) or butaprost (10 μM). Results ($[^3H]$-cAMP, %, see Methods) are from donor 1 ($n = 6$-8), but were confirmed in donor 2. $^*P < 0.05$, one-way repeated measures ANOVA with Dunnett's test, relative to basal. F, Effects of ESI-05 (25 μM, 30 min) in HBS on the Ca^{2+} signals evoked by histamine (10 μM) added 1 min after the indicated concentrations of isoproterenol. Results are expressed as percentages of matched responses to histamine in the absence of isoproterenol (donors 1 and 2, $n = 9$).

we suggest that PKA probably mediates most relaxant effects of isoproterenol in human ASM [5] and it is therefore likely also to mediate the effects of isoproterenol on histamine-evoked Ca^{2+} signals. That conclusion is also consistent with recent analyses of human aortic smooth muscle, where selective inhibition of histamine-evoked Ca^{2+} signals by PGE_2 was shown to be mediated by PKA [43].

3.3. Isoproterenol signals to Ca^{2+} signals through compartmentalized cAMP

During sustained incubation with isoproterenol, cAMP continued to accumulate for at least 30 min, such that the stimulated cAMP concentration was 2.8-fold higher after 30 min than after 1 min (Fig. 5Bi). However, the inhibition of Ca^{2+} signals was similar when hBASMCs

were pre-incubated with isoproterenol for intervals between 1 and 30 min before addition of histamine (Fig. 5Bii, Biii). Hence, even though cAMP continued to accumulate long after the first minute of stimulation with isoproterenol, neither the maximal inhibition of histamine-evoked Ca^{2+} signals nor their sensitivity (pIC_{50}) to isoproterenol was increased by prolonging the incubation (Fig. 5B). Since maximal activation of β_2-adrenoceptors provides more cAMP than needed to maximally inhibit histamine-evoked Ca^{2+} signal, it is unsurprising that prolonged incubation with a maximally effective concentration of isoproterenol caused no further inhibition of Ca^{2+} signals. However, when cAMP entirely mediates the effects of isoproterenol (Fig. 4), it is surprising that the sensitivity of histamine-evoked Ca^{2+} signals to isoproterenol is unaffected by prolonged incubations during

Fig. 5. Compartmentalized cAMP inhibits histamine-evoked Ca^{2+} signals. A, Effects of pre-treatment (30 min) with the indicated inhibitors and then isoproterenol (1 min) on the Ca^{2+} signals evoked by histamine (10 μM). Results (donors 1 and 2, $n = 9$) show the peak Ca^{2+} signals (as percentages of matched responses to histamine without isoproterenol) and their sensitivity to inhibition by isoproterenol (pIC_{50}). *$P < 0.05$, one-way repeated measures ANOVA with Dunnett's test, relative to control. B, Effects of varying the duration of the incubation with isoproterenol (10 μM) on cAMP accumulation (i) and the peak Ca^{2+} signals evoked by histamine (10 μM) (ii and iii). Accumulation of intracellular cAMP was measured after ^{3}H-adenine labeling ([^{3}H]-cAMP, %). Results for $\Delta[Ca^{2+}]_i$ show the peak response as a percentage of that evoked by histamine alone (ii) and the pIC_{50} value for isoproterenol (iii). ($n = 4$). C, Relationship between intracellular cAMP (determined by MS) and the inhibition of Ca^{2+} signals evoked by histamine (10 μM) in cells where the increase in cAMP was evoked by incubation with different concentrations of IBMX (20 min) or isoproterenol (5 min). Each point includes data from 5 (IBMX) or 3 (isoproterenol) MS determination of cAMP associated with 6 (IBMX) or 4 (isoproterenol) measurements of $[Ca^{2+}]_i$. Results (B and C) are from cells from donor 1.

which more intracellular cAMP accumulates (Fig. 5B). Inhibition of Ca^{2+} signals by β_2-adrenoceptors cannot, therefore, be mediated by cAMP uniformly distributed throughout the cytosol.

Whereas GPCRs may locally deliver cAMP at high concentrations to targets within signaling junctions [28 and references therein], this is less likely for cAMP accumulated after addition of IBMX, a non-selective inhibitor of cyclic nucleotide phosphodiesterases (Fig. 4B). We therefore compared the relationship between intracellular cAMP and inhibition of histamine-evoked Ca^{2+} signals, for cAMP responses evoked by IBMX or isoproterenol. For matched Ca^{2+} signals, the inhibition evoked by isoproterenol was associated with ~5.4-fold higher concentrations of intracellular cAMP than for IBMX (Fig. 5C). These results again suggest that histamine-evoked Ca^{2+} signals are not regulated by globally distributed cAMP.

3.4. PGE₂ inhibits histamine-evoked Ca²⁺ signals through both EP₂ and EP₄ receptors

In hBASMCs, PGE₂ stimulated cAMP accumulation (Fig. 4E) but, unlike isoproterenol or forskolin, PGE₂ directly evoked a significant increase in $[Ca^{2+}]_i$ (Fig. 6A). This response was probably mediated by EP₃ receptors because sulprostone, a selective agonist of G_i-coupled EP₃ receptors [46], also evoked an increase in $[Ca^{2+}]_i$ (Fig. 6B).

In subsequent experiments, butaprost and TCS2510 were used to selectively stimulate EP₂ and EP₄ receptors, respectively. Both receptors are known to stimulate Gs and thereby AC activity [47,48]. Neither butaprost nor TCS2510 evoked an increase in $[Ca^{2+}]_i$ (results not shown), but both stimulated formation of cAMP and inhibited the Ca^{2+}

signals evoked by histamine (Fig. 4D, E). Although a maximal concentration of TCS2510 was as effective as forskolin, NKH477, isoproterenol or butaprost in inhibiting histamine-evoked Ca^{2+} signals, it evoked far less production of cAMP (Fig. 4E). This suggests that maximal activation of EP₂ receptors (by butaprost), like maximal activation of β-adrenoceptors (by isoproterenol), evokes formation of more cAMP than needed to cause maximal inhibition of histamine-evoked Ca^{2+} signals. Our results are consistent with evidence that human ASM express EP₂, EP₃ and EP₄ receptors, that EP₃ receptors evoke an increase in $[Ca^{2+}]_i$, that both EP₂ and EP₄ receptors stimulate accumulation of cAMP [26], and with recent evidence showing that EP₂ receptors evoke local cAMP signals in human ASM [28]. PGE₂ causes relaxation of histamine-contracted human airways, but conflicting reports have suggested that this is mediated entirely through EP₂ [27] or EP₄ receptors [22]. Our results provide the first evidence that both EP₂ and EP₄ receptors inhibit histamine-evoked Ca^{2+} signals in human ASM.

3.5. Ca²⁺ signals evoked by different GPCRs differ in their susceptibility to inhibition by cAMP

Fig. 6C–F compares the effects of activating AC directly (with forskolin) or via G_s-coupled GPCRs (β₂-adrenoceptors, EP₂ or EP₄ receptors) on the Ca^{2+} signals evoked by histamine, LPA, bradykinin or carbachol in hBASMCs. The results confirm the substantial inhibition of histamine-evoked Ca^{2+} signals by cAMP, but the Ca^{2+} signals evoked by carbachol and bradykinin were unaffected by any of the cAMP-elevating stimuli. Analyses of single fura 2-loaded cells confirmed that all cells responded to both histamine and bradykinin with an increase in

Fig. 6. Ca^{2+} signals evoked by different GPCRs differ in their susceptibility to inhibition by cAMP. A, Peak increases in $[Ca^{2+}]_i$ evoked by isoproterenol (10 μM), PGE_2 (10 μM) or forskolin (10 μM) in Ca^{2+}-free HBS ($n = 7$ from donors 1 and 2). $^*P < 0.05$, one-way ANOVA with Dunnett's test, relative to control. B, Peak increases in $[Ca^{2+}]_i$ evoked by PGE_2 or sulprostone in Ca^{2+}-free HBS (BAPTA added 37 s before the stimuli) ($n = 3$ from donors 1 and 2). C-F, hBASMCs in HBS were pre-treated (5 min) with isoproterenol (10 μM), forskolin (10 μM), butaprost (10 μM), TCS2510 (1 μM) or solvents, and then stimulated with the indicated concentrations of histamine (C), bradykinin (D), carbachol (E) or LPA (F). The code in C applies to panels C-F. Results show peak increases in $[Ca^{2+}]_i$ evoked by the final stimulus from 6 independent experiments from donors 1 and 2 (C, D and F), and from 3 independent experiments with donor 2 (E). (G, H) Similar analyses of cells in HBS after treatment with pertussis toxin (PTX, 100 ng·mL^{-1}, 24 h). The code in G applies also to H. Results are from 3 independent experiments from donor 2 (G) and donors 1 and 2 (H).

$[Ca^{2+}]_i$ (results not shown). The differential susceptibility of the Ca^{2+} signals evoked by histamine and bradykinin to inhibition by cAMP is not therefore due to differential distribution of their receptors between cells.

Activation of M_2 receptors by carbachol might, via G_i, have counteracted the increases in cAMP evoked by forskolin or the G_s-coupled GPCRs [12,38]. However, the Ca^{2+} signals evoked by carbachol or bradykinin remained insensitive to isoproterenol after treatment with pertussis toxin (Fig. 6G, H). Parallel experiments demonstrated that the treatment with PTX was sufficient to abolish the inhibition of AC activity by carbachol (results not shown) and to attenuate the Ca^{2+} signals evoked by carbachol and LPA (Fig. 2C-F). These results demonstrate that cAMP selectively inhibits the Ca^{2+} signals evoked by histamine.

4. Discusssion

Our analyses of hBASMCs show that histamine evokes cytosolic Ca^{2+} signals by stimulating PLC and release of Ca^{2+} through IP_3Rs (Fig. 1A–D). Similar mechanisms probably underlie the Ca^{2+} signals evoked by carbachol, bradykinin and LPA (Fig. 1B–D). The four stimuli do, however, differ in the extent to which they regulate PLC exclusively through $G_{q/11}$ (histamine and bradykinin) or with some contribution from Gi (LPA, and to a lesser extent carbachol) (Figs. 2, 6G, H and 7A). These results concur with those from human lung slices, where contractions evoked by carbachol or histamine were substantially attenuated by inhibitors of $G_{q/11}$ [49], although the specificity of one of the inhibitors (UBO-QIC) has been challenged [50].

The Ca^{2+} signals evoked by histamine were attenuated by

A

B

Inhibition of histamine-evoked Ca²⁺ signals

stimulation of $β_2$-adrenoceptors, consistent with results from human lung slices where formoterol caused a long-lasting inhibition of histamine-evoked Ca^{2+} oscillations [19]. In our analyses, the inhibition was mimicked by stimulation of EP_2 or EP_4 receptors, 8-Br-cAMP, direct activation of AC, or by inhibition of cyclic nucleotide PDEs (Figs. 3–6). These results and the non-additive inhibition of Ca^{2+} signals by maximally effective concentrations of forskolin and isoproterenol (Fig. 4C) establish that inhibition of histamine-evoked Ca^{2+} signals by $β_2$-adrenoceptors is entirely mediated by cAMP. The inhibition is not mediated by activation of epacs (Fig. 4F and 5A), but our attempts to demonstrate a need for PKA were thwarted by ineffective inhibitors (Fig. 5A)[for further discussion see [5], 43]. However while our work was in progress, inhibition of histamine-evoked Ca^{2+} signals by isoproterenol was shown to be prevented by viral infection with a peptide inhibitor of PKA [5]. Hence, we suggest that in hBASMCs inhibition of histamine-evoke Ca^{2+} signals by $β_2$-adrenoceptors is entirely mediated by cAMP and PKA (Fig. 7A).

The inhibition of GPCR-evoked Ca^{2+} signals by cAMP was selective for histamine. The Ca^{2+} signals evoked by bradykinin and carbachol were insensitive to cAMP, while cAMP caused only a modest and inconsistent inhibition of responses to LPA (Figs. 6C–H and 7A).

Isoproterenol can cause relaxation of airways in human lung slices contracted with carbachol [12], but the contractions evoked by muscarinic receptors are more resistant to the relaxant effects of $β_2$-adrenoceptors than the contractions evoked by histamine [38,51–53]. These results are consistent with our findings, and suggest that a reduction in the sensitivity of the contractile apparatus to Ca^{2+} by cAMP may reduce contractions evoked by all contractile stimuli [19], while the response to histamine is further reduced by attenuation of the Ca^{2+} signals. Selective inhibition of histamine-evoked Ca^{2+} signals by PKA suggests a target close to the histamine H_1 receptor, and perhaps the receptor itself [see discussion in reference [43]] (Fig. 7A).

Although cAMP entirely mediates the inhibition of histamine-evoked Ca^{2+} signals by $β_2$-adrenoceptors, there is no consistent relationship between intracellular cAMP and inhibition of Ca^{2+} signals under different stimulation conditions (Fig. 5C). This suggests an intracellular compartmentalization of the effective cAMP [28]. The cAMP produced immediately after activation of $β_2$-adrenoceptors most effectively inhibits Ca^{2+} signals, but the sensitivity to isoproterenol is unchanged during sustained stimulation despite further accumulation of cAMP. This suggests that local regulation of histamine responses must continue throughout the sustained stimulation, but this is accompanied

by diffusion of cAMP, which then accumulates in cytoplasmic regions where it does not effectively inhibit histamine responses (Fig. 5B). This slow accumulation of 'ineffective' cAMP would provide an explanation for our observation that as cAMP accumulates during sustained iso-proterenol stimulation neither the maximal inhibition of histamine-evoked Ca^{2+} signals nor their sensitivity to isoproterenol increases (Fig. 5B). But why should globally distributed cAMP arising from in-hibition of cyclic nucleotide PDEs appear more effective than cAMP delivered from β_2-adrenoceptors (Fig. 5C)? We suggested previously that signaling from AC-coupled GPCRs to effector systems may occur within 'hyperactive' signaling junctions [43,54,55] (Fig. 7B). These, we propose, serve as digital switches, wherein activation of a junction generates more cAMP than required to fully activate associated PKA. The concentration-dependent effects of extracellular stimuli are pro-posed to arise from recruitment of active junctions, rather than from graded activity within individual junctions (Fig. 7B). Hence, each junction would behave as a robust on-off switch, locally saturating the neighboring PKA for as long as the GPCR stimulates AC. The benefits of this mode of signaling include speed, reliability and opportunities for local targeting of cAMP. Since inhibition of histamine-evoked Ca^{2+} signals by β_2-adrenoceptors is associated with higher overall levels of intracellular cAMP than comparable inhibition with IBMX (Fig. 5C), we suggest that hyperactive cAMP signaling junctions mediate the com-munication between β_2-adrenoceptors, PKA and histamine responses (Fig. 7B).

We conclude that cAMP selectively inhibits the Ca^{2+} signals evoked by histamine in hBASMCs. Communication between the GPCRs that stimulate AC and the PKA that mediates the inhibition occurs within hyperactive signaling junctions. These junctions, which may be a gen-eral feature of cAMP signaling, allow rapid, robust and specific com-munication between receptors and effectors [43,54,55].

Author contributions

PD performed and analysed most experiments. VH completed the MS analysis of cAMP samples, with input from MRD. CWT supervised the project and contributed to analysis. CWT. CWT and PD wrote the paper. All authors reviewed the paper.

Conflict of interest

VH and MRD are employees of Novartis, which manufactures drugs used to treat respiratory diseases. CWT and PD declare that they have no competing financial interests.

Acknowledgements

References

[1] P.J. Barnes, K.F. Chung, C.P. Page, Inflammatory mediators of asthma: an update, Pharmacol. Rev. 50 (1998) 515–596.

[2] P.J. Barnes, Mediators of chronic obstructive pulmonary disease, Pharmacol. Rev. 56 (2004) 515–548.

[3] E.D. Bateman, S.S. Hurd, P.J. Barnes, J. Bousquet, J.M. Drazen, M. FitzGerald, et al., Global strategy for asthma management and prevention: GINA executive summary, Eur. Respir. J. 31 (2008) 143–178.

[4] P.R. Dale, H. Cernecka, M. Schmidt, M.R. Dowling, S.J. Charlton, M.P. Pieper, et al., The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease, Curr. Opin. Pharm. 16 (2014) 31–42.

[5] S.J. Morgan, D.A. Deshpande, B.C. Tiegs, A.M. Misior, H. Yan, A.V. Hershfeld, et al., β-Agonist-mediated relaxation of airway smooth muscle is protein kinase A-de-pendent, J. Biol. Chem. 289 (2014) 23065–23074.

[6] S.J. Bradley, C.H. Wiegman, M.M. Iglesias, K.C. Kong, A.J. Butcher, B. Plouffe, et al., Mapping physiological G protein-coupled receptor signaling pathways reveals

[7] H. Sakai, S. Otogoto, Y. Chiba, K. Abe, M. Misawa, Involvement of p42/44 MAPK and RhoA protein in augmentation of ACh-induced bronchial smooth muscle con-traction by TNF-alpha in rats, J. Appl. Physiol. 97 (2004) 2154–2159.

[8] F.C. Tao, B. Tolloczko, D.H. Eidelman, J.G. Martin, Enhanced Ca^{2+} mobilization in airway smooth muscle contributes to airway hyperresponsiveness in an inbred strain of rat, Am. J. Respir. Crit. Care Med. 160 (1999) 446–453.

[9] K. Mahn, S.J. Hirst, S. Ying, M.R. Holt, P. Lavender, O.O. Ojo, et al., Diminished sarco/endoplasmic reticulum Ca^{2+} ATPase (SERCA) expression contributes to airway remodelling in bronchial asthma, Proc. Natl. Acad. Sci. USA 106 (2009) 10775–10780.

[10] V. Sathish, M.A. Thompson, J.P. Bailey, C.M. Pabelick, Y.S. Prakash, G.C. Sieck, Effect of proinflammatory cytokines on regulation of sarcoplasmic reticulum Ca^{2+} reuptake in human airway smooth muscle, Am. J. Physiol. 297 (2009) L26–L34.

[11] H. Meurs, A. Timmermans, R.G. Van Amsterdam, F. Brouwer, H.F. Kauffman, J. Zaagsma, Muscarinic receptors in human airway smooth muscle are coupled to phosphoinositide metabolism, Eur. J. Pharmacol. 164 (1989) 369–371.

[12] S.M. Brown, A. Koarai, R.G. Sturton, A.G. Nicholson, P.J. Barnes, L.E. Donnelly, A role for M_2 and M_3 muscarinic receptors in the contraction of rat and human small airways, Eur. J. Pharmacol. 702 (2013) 109–115.

[13] A.R. Hulsmann, H.R. Raatgeep, P.R. Saxena, K.F. Kerrebijn, J.C. de Jongste, Bradykinin-induced contraction of human peripheral airways mediated by both bradykinin beta 2 and thromboxane prostanoid receptors, Am. J. Respir. Crit. Care Med. 150 (1994) 1012–1018.

[14] R.G. Van Amsterdam, H. Meurs, F. Brouwer, J.B. Postema, A. Timmermans, J. Zaagsma, Role of phosphoinositide metabolism in functional antagonism of airway smooth muscle contraction by β-adrenoceptor agonists, Eur. J. Pharmacol. 172 (1989) 175–183.

[15] L.J. Janssen, T. Tazzeo, J. Zuo, Enhanced myosin phosphatase and Ca^{2+}-uptake mediate adrenergic relaxation of airway smooth muscle, Am. J. Resp. Cell Mol. Biol. 30 (2004) 548–554.

[16] Y. Bai, M. Edelmann, M.J. Sanderson, The contribution of inositol 1,4,5-trispho-sphate and ryanodine receptors to agonist-induced Ca^{2+} signaling of airway smooth muscle cells, Am. J. Physiol. 297 (2009) L347–L361.

[17] L. Spicuzza, M.G. Belvisi, M.A. Birrell, P.J. Barnes, D.J. Hele, M.A. Giembycz, Evidence that the anti-spasmogenic effect of the beta-adrenoceptor agonist iso-prenaline, on guinea-pig trachealis is not mediated by cyclic AMP-dependent pro-tein kinase, Br. J. Pharmacol. 133 (2001) 1201–1212.

[18] S.S. Roscioni, H. Maarsingh, C.R. Elzinga, J. Schuur, M. Menzen, A.J. Halayko, et al., Epac as a novel effector of airway smooth muscle relaxation, J. Cell. Mol. Med. 15 (2011) 1551–1563.

[19] A.R. Ressmeyer, Y. Bai, P. Delmotte, K.F. Uy, P. Thistlethwaite, A. Fraire, et al., Human airway contraction and formoterol-induced relaxation is determined by Ca^{2+} oscillations and Ca^{2+} sensitivity, Am. J. Resp. Cell Mol. Biol. 43 (2010) 179–191.

[20] I.P. Hall, M. Kotlikoff, Use of cultured airway myocytes for study of airway smooth muscle, Am. J. Physiol. 268 (1995) L1–L11.

[21] S. Widdop, K. Daykin, I.P. Hall, Expression of muscarinic M_2 receptors in cultured human airway smooth muscle cells, Am. J. Resp. Cell Mol. Biol. 9 (1993) 541–546.

[22] J. Buckley, M.A. Birrell, S.A. Maher, A.T. Nials, D.L. Clarke, M.G. Belvisi, EP_4 re-ceptor as a new target for bronchodilator therapy, Thorax 66 (2011) 1029–1035.

[23] T. Ozaki, S.I. Rennard, R.G. Crystal, Cyclooxygenase metabolites are compart-mentalized in the human lower respiratory tract, J. Appl. Physiol. 62 (1987) 219–222.

[24] B. Sastre, M. Fernandez-Nieto, R. Molla, E. Lopez, C. Lahoz, J. Sastre, et al., Increased prostaglandin E_2 levels in the airway of patients with eosinophilic bronchitis, Allergy 63 (2008) 58–66.

[25] J.K. Burgess, Q. Ge, S. Boustany, J.L. Black, P.R. Johnson, Increased sensitivity of asthmatic airway smooth muscle cells to prostaglandin E_2 might be mediated by increased numbers of E-prostanoid receptors, J. Allergy Clin. Immunol. 113 (2004) 876–881.

[26] A. Mori, S. Ito, M. Morioka, H. Aso, M. Kondo, M. Sokabe, et al., Effects of specific prostanoid EP receptor agonists on cell proliferation and intracellular Ca^{2+} con-centrations in human airway smooth muscle cells, Eur. J. Pharmacol. 659 (2011) 72–78.

[27] X. Norel, L. Walch, C. Labat, J.P. Gascard, E. Dulmet, C. Brink, Prostanoid receptors involved in the relaxation of human bronchial preparations, Br. J. Pharmacol. 126 (1999) 867–872.

[28] S.R. Agarwal, K. Miyashiro, H. Latt, R.S. Ostrom, R.D. Harvey, Compartmentalized cAMP responses to prostaglandin EP_2 receptor activation in human airway smooth muscle cells, Br. J. Pharmacol. 174 (2017) 2784–2796.

[29] G. Grynkiewicz, M. Poenie, R.Y. Tsien, A new generation of Ca^{2+} indicators with greatly improved fluorescence properties, J. Biol. Chem. 260 (1985) 3440–3450.

[30] Y. Salomon, C. Londos, M. Rodbell, A highly sensitive adenylate cyclase assay, Anal. Biochem. 58 (1974) 541–548.

[31] W. Goutier, P.A. Spaans, M.A. van der Neut, A.C. McCreary, J.H. Reinders, Development and application of an LC-MS/MS method for measuring the effect of (partial) agonists on cAMP accumulation in vitro, J. Neurosci. Methods 188 (2010) 24–31.

[32] E. Naylor, A. Arredouani, S.R. Vasudevan, A.M. Lewis, R. Parkesh, A. Mizote, et al., Identification of a chemical probe for NAADP by virtual screening, Nat. Chem. Biol. 5 (2009) 220–226.

[33] X. Wang, X. Zhang, X.P. Dong, M. Samie, X. Li, X. Cheng, et al., TPC proteins are phosphoinositide-activated sodium-selective ion channels in endosomes and lyso-somes, Cell 151 (2012) 372–383.

[34] E. Pantazaka, E.J.A. Taylor, W. Bernard, C.W. Taylor, Ca^{2+} signals evoked by histamine H_1 receptors are attenuated by activation of prostaglandin EP_2 receptors in human aortic smooth muscle, Br. J. Pharmacol. 169 (2013) 1624–1634.

[35] M.J. Seewald, R.A. Olsen, I. Sehgal, D.C. Melder, E.J. Modest, G. Powis, Inhibition of growth factor-dependent inositol phosphate Ca^{2+} signaling by antitumor ether lipid analogues, Cancer Res. 50 (1990) 4458–4463.

[36] H. Saleem, S.C. Tovey, T.F. Molinski, C.W. Taylor, Interactions of antagonists with subtypes of inositol 1,4,5-trisphosphate (IP_3) receptor, Br. J. Pharmacol. 171 (2014) 3298–3312.

[37] C.M. Peppiatt, T.J. Collins, L. Mackenzie, S.J. Conway, A.B. Holmes, M.D. Bootman, et al., 2-Aminoethoxydiphenyl borate (2-APB) antagonises inositol 1,4,5-trisphosphate-induced calcium release, inhibits calcium pumps and has a use-dependent and slowly reversible action on store-operated calcium entry channels, Cell Calcium 34 (2003) 97–108.

[38] B. Sarria, E. Naline, Y. Zhang, J. Cortijo, M. Molimard, J. Moreau, et al., Muscarinic M_2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus, Am. J. Physiol. 283 (2002) L1125–L1132.

[39] S. Strickland, J.N. Loeb, Obligatory separation of hormone binding and biological response curves in systems dependent upon secondary mediators of hormone action, Proc. Natl. Acad. Sci. USA 78 (1981) 1366–1370.

[40] A.E. Christensen, F. Selheim, J. de Roooij, S. Dremier, F. Schwede, K.K. Dao, et al., cAMP analog mapping of epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act syneristically to promote PC12 cell neurite extension, J. Biol. Chem. 278 (2003) 35394–35402.

[41] T. Tsalkova, F.C. Mei, S. Li, O.G. Chepurny, C.A. Leech, T. Liu, et al., Isoform-specific antagonists of exchange proteins directly activated by cAMP, Proc. Natl. Acad. Sci. USA 109 (2012) 18613–18618.

[42] A. Meena, S.C. Tovey, C.W. Taylor, Sustained signalling by PTH modulates IP_3 accumulation and IP_3 receptors via cyclic AMP junctions, J. Cell Sci. 128 (2015) 408–420.

[43] E.J.A. Taylor, E. Pantazaka, K.L. Shelley, C.W. Taylor, Prostaglandin E_2 inhibits histamine-evoked Ca^{2+} release in human aortic smooth muscle cells through hyperactive cAMP signalling junctions and protein kinase A, Mol. Pharmacol. 92 (2017) 533–545.

[44] M. Guo, R.M. Pascual, S. Wang, M.F. Fontana, C.A. Valancius, R.A. Panettieri, Jr.et al., Cytokines regulate β-2-adrenergic receptor responsiveness in airway smooth muscle via multiple PKA- and EP_2 receptor-dependent mechanisms, Biochemistry 44 (2005) 13771–13782.

[45] R.B. Penn, J.L. Parent, A.N. Pronin, R.A. Panettieri, Jr., J.L. Benovic, Pharmacological inhibition of protein kinases in intact cells: antagonism of β adrenergic receptor ligand binding by H-89 reveals limitations of usefulness, J. Pharmacol. Exp. Ther. 288 (1999) 428–437.

[46] M. Abramovitz, M. Adam, Y. Boie, M. Carriere, D. Denis, C. Godbout, et al., The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs, Biochim. Biophys. Acta 1483 (2000) 285–293.

[47] X. Billot, A. Chateauneuf, N. Chauret, D. Denis, G. Greig, M.C. Mathieu, et al., Discovery of a potent and selective agonist of the prostaglandin EP_4 receptor, Bioorg. Med. Chem. Lett. 13 (2003) 1129–1132.

[48] R.J. Wilson, S.A. Rhodes, R.L. Wood, V.J. Shield, L.S. Noel, D.W. Gray, et al., Functional pharmacology of human prostanoid EP_2 and EP_4 receptors, Eur. J. Pharmacol. 501 (2004) 49–58.

[49] R. Carr 3rd, C. Koziol-White, J. Zhang, H. Lam, S.S. An, G.G. Tall, et al., Interdicting Gq activation in airway disease by receptor-dependent and receptor-independent mechanisms, Mol. Pharmacol. 89 (2015) 94–104.

[50] Z.G. Gao, K.A. Jacobson, On the selectivity of the Ga_q inhibitor UBO-QIC: A comparison with the Ga_i inhibitor pertussis toxin, Biochem. Pharmacol. 107 (2016) 59–66.

[51] E. Naline, A. Trifilieff, R.A. Fairhurst, C. Advenier, M. Molimard, Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi, Eur. Respir. J. 29 (2007) 575–581.

[52] B. Raffestin, J. Cerrina, C. Boullet, C. Labat, J. Benveniste, C. Brink, Response and sensitivity of isolated human pulmonary muscle preparations to pharmacological agents, J. Pharmacol. Exp. Ther. 233 (1985) 186–194.

[53] N. Watson, H. Magnussen, K.F. Rabe, Antagonism of beta-adrenoceptor-mediated relaxations of human bronchial smooth muscle by carbachol, Eur. J. Pharmacol. 275 (1995) 307–310.

[54] S.C. Tovey, S.G. Dedos, E.J.A. Taylor, J.E. Church, C.W. Taylor, Selective coupling of type 6 adenylyl cyclase with type 2 IP_3 receptors mediates a direct sensitization of IP_3 receptors by cAMP, J. Cell Biol. 183 (2008) 297–311.

[55] C.W. Taylor, Regulation of IP_3 receptors by cyclic AMP, Cell Calcium 63 (2017) 48–52.